UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

The Lancet (British edition), 2015-08, Vol.386 (9993), p.541-551

2015

Volltextzugriff (PDF)

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

The New England journal of medicine, 2016-07, Vol.375 (4), p.345-356

2016

Volltextzugriff (PDF)

A qualitative study exploring the health-related quality of life and symptomatic experiences of adults and adolescents with ulcerative colitis

Journal of patient-reported outcomes, 2019-10, Vol.3 (1), p.1-13, Article 66

2019

Volltextzugriff (PDF)

Efficacy and Safety of Tadalafil Once Daily in the Treatment of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results of an International Randomized, Double-Blind, Placebo-Controlled Trial

European urology, 2011-11, Vol.60 (5), p.1105-1113

2011

Volltextzugriff (PDF)

Effects of Tadalafil on Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia and on Erectile Dysfunction in Sexually Active Men with Both Conditions: Analyses of Pooled Data from Four Randomized, Placebo‐Controlled Tadalafil Clinical Studies

Journal of sexual medicine, 2013-08, Vol.10 (8), p.2044-2052

2013

Volltextzugriff (PDF)

Tadalafil 2.5 or 5 mg Administered Once Daily for 12 Weeks in Men with Both Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia: Results of a Randomized, Placebo‐Controlled, Double‐Blind Study

Journal of sexual medicine, 2012-01, Vol.9 (1), p.271-281

2012

Volltextzugriff (PDF)

Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of Raloxifene Evaluation trial

Bone (New York, N.Y.), 2003-09, Vol.33 (3), p.293-300

2003

Volltextzugriff (PDF)

Reply to Ege Can Serefoglu, Gregory C. Mitchell, and Wayne J.G. Hellstrom’s Letter to the Editor re: Hartmut Porst, Edward D. Kim, Adolfo R. Casabé, et al., for the LVHJ study team. Efficacy and Safety of Tadalafil Once Daily in the Treatment of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results of an International Randomized, Double-Blind, Placebo-Controlled Trial. Eur Urol 2011;60:1105–13

European urology, 2012-05, Vol.61 (5), p.e47-e48

2012

Volltextzugriff (PDF)

Tadalafil Administered Once Daily for Treatment of Lower Urinary Tract Symptoms in Korean men with Benign Prostatic Hyperplasia: Results from a Placebo-Controlled Pilot Study Using Tamsulosin as an Active Control

Lower urinary tract symptoms, 2011-09, Vol.3 (2), p.86-93

2011

Volltextzugriff (PDF)

The Role of Selective Estrogen Receptor Modulators in the Prevention of Breast Cancer: Comparison of the Clinical Trials

The oncologist (Dayton, Ohio), 2004-01, Vol.9 (2), p.116-125

2004

Volltextzugriff (PDF)

Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis

Current medical research and opinion, 2008-03, Vol.24 (3), p.807-813

2008

Volltextzugriff (PDF)

Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women

American journal of obstetrics and gynecology, 2003-02, Vol.188 (2), p.389-394

2003

Volltextzugriff (PDF)

Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene

JNCI : Journal of the National Cancer Institute, 2004-12, Vol.96 (23), p.1751-1761

2004

Volltextzugriff (PDF)

RESPONSE: Re: Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene

JNCI : Journal of the National Cancer Institute, 2005-04, Vol.97 (7), p.542-543

2005

Volltextzugriff (PDF)

Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene

JNCI : Journal of the National Cancer Institute, 2005-04, Vol.97 (7), p.542-543

2005

Volltextzugriff (PDF)

Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of Raloxifene Evaluation trial11Eli Lilly and Company (Indianapolis, IN) sponsored the Multiple Outcomes of Raloxifene Evaluation (MORE) trial

Bone (New York, N.Y.), 2003-09, Vol.33 (3), p.293-300

2003

Volltextzugriff (PDF)

Selective estrogen receptor modulators: mechanism of action and clinical experience. Focus on raloxifene

Reproduction fertility and development, 2001, Vol.13 (4), p.331

2001

Volltextzugriff (PDF)

Endothelin: Differential effects in vascular and nonvascular smooth muscle

Life sciences (1973), 1989, Vol.45 (15), p.1365-1372

1989

Volltextzugriff (PDF)

Leukotriene D4 Relaxes Canine Renal and Superior Mesenteric Arteries

Circulation research, 1985-08, Vol.57 (2), p.323-329

1985

Volltextzugriff (PDF)

Endothelial-Dependent Relaxation Induced by Leukotrienes C4, D4, and E4 in Isolated Canine Arteries

Circulation research, 1988-05, Vol.62 (5), p.983-991

1988

Volltextzugriff (PDF)

Hypotensive Properties of the Protein Kinase Inhibitor, Staurosporine, in Normotensive and Spontaneously Hypertensive Rats

Clinical and experimental hypertension (1993), 1991, Vol.A13 (2), p.219-234

1991

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Humans
(11)
Middle Aged
(10)
Female
(9)
Aged
(8)
Biological And Medical Sciences
(8)
Male
(8)
Raloxifene Hydrochloride - Therapeutic Use
(6)
Double-Blind Method
(5)
Medical Sciences
(5)
Selective Estrogen Receptor Modulators - Therapeutic Use
(5)
Treatment Outcome
(5)
Urology & Nephrology
(5)
Adult
(4)
Animals
(4)
Benign Prostatic Hyperplasia
(4)
Raloxifene
(4)
Tadalafil
(4)
Breast Cancer
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

A qualitative study exploring the health-related quality of life and symptomatic experiences of adults and adolescents with ulcerative colitis

Efficacy and Safety of Tadalafil Once Daily in the Treatment of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results of an International Randomized, Double-Blind, Placebo-Controlled Trial

Effects of Tadalafil on Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia and on Erectile Dysfunction in Sexually Active Men with Both Conditions: Analyses of Pooled Data from Four Randomized, Placebo‐Controlled Tadalafil Clinical Studies

Tadalafil 2.5 or 5 mg Administered Once Daily for 12 Weeks in Men with Both Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia: Results of a Randomized, Placebo‐Controlled, Double‐Blind Study

Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of Raloxifene Evaluation trial

Tadalafil Administered Once Daily for Treatment of Lower Urinary Tract Symptoms in Korean men with Benign Prostatic Hyperplasia: Results from a Placebo-Controlled Pilot Study Using Tamsulosin as an Active Control

The Role of Selective Estrogen Receptor Modulators in the Prevention of Breast Cancer: Comparison of the Clinical Trials

Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis

Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women

Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene

RESPONSE: Re: Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene

Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene

Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of Raloxifene Evaluation trial11Eli Lilly and Company (Indianapolis, IN) sponsored the Multiple Outcomes of Raloxifene Evaluation (MORE) trial

Selective estrogen receptor modulators: mechanism of action and clinical experience. Focus on raloxifene

Endothelin: Differential effects in vascular and nonvascular smooth muscle

Leukotriene D4 Relaxes Canine Renal and Superior Mesenteric Arteries

Endothelial-Dependent Relaxation Induced by Leukotrienes C4, D4, and E4 in Isolated Canine Arteries

Hypotensive Properties of the Protein Kinase Inhibitor, Staurosporine, in Normotensive and Spontaneously Hypertensive Rats

Suchergebnisse filtern